SPECIALTY QUANTITY LIMIT PROGRAM

TAZVERIK (tazemetostat)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Tazverik (tazemetostat) 200 mg tablets	240 per 30 days	Epithelioid Sarcoma: 800 mg twice daily Dose reduction: 600 mg to 200 mg orally twice daily

III. REFERENCES

1. Tazverik [package insert]. Cambridge, MA: Epizyme, Inc.; January 2020.

DOCUMENT HISTORY

Created: Specialty Clinical Development (JL) 01/2020 Revised: Reviewed: CHART 02/06/2020 External Review: 02/2020

Specialty Quantity Limit Tazverik 3504-H P2020.docx

© 2020 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

